These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 30024493)

  • 1. High Completion Rate for 12 Weekly Doses of Isoniazid and Rifapentine as Treatment for Latent Mycobacterium tuberculosis Infection in the Federal Bureau of Prisons.
    Schmit KM; Lobato MN; Lang SG; Wheeler S; Kendig NE; Bur S
    J Public Health Manag Pract; 2019; 25(2):E1-E6. PubMed ID: 30024493
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of Rifapentine and Isoniazid Directly Observed Therapy for the Treatment of Latent Tuberculosis Infection in a Military Clinic.
    Jinbo J; Lustik M; West GF; Kloetzel M
    Mil Med; 2017 Sep; 182(9):e2024-e2029. PubMed ID: 28885972
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Management of Latent Tuberculosis Infection Among Healthcare Workers: 10-Year Experience at a Single Center.
    Arguello Perez E; Seo SK; Schneider WJ; Eisenstein C; Brown AE
    Clin Infect Dis; 2017 Nov; 65(12):2105-2111. PubMed ID: 29020308
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Twelve-Week Rifapentine Plus Isoniazid Versus 9-Month Isoniazid for the Treatment of Latent Tuberculosis in Renal Transplant Candidates.
    Simkins J; Abbo LM; Camargo JF; Rosa R; Morris MI
    Transplantation; 2017 Jun; 101(6):1468-1472. PubMed ID: 27548035
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improving Treatment Completion Rates for Latent Tuberculosis Infection: A Review of Two Treatment Regimens at a Community Health Center.
    Lines G; Hunter P; Bleything S
    J Health Care Poor Underserved; 2015 Nov; 26(4):1428-39. PubMed ID: 26548690
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Completion Rates, Adverse Effects, and Costs of a 3-Month and 9-Month Treatment Regimen for Latent Tuberculosis Infection in California Inmates, 2011-2014.
    Wheeler C; Mohle-Boetani J
    Public Health Rep; 2019; 134(1_suppl):71S-79S. PubMed ID: 31059418
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impacts of 12-dose regimen for latent tuberculosis infection: Treatment completion rate and cost-effectiveness in Taiwan.
    Huang YW; Yang SF; Yeh YP; Tsao TC; Tsao SM
    Medicine (Baltimore); 2016 Aug; 95(34):e4126. PubMed ID: 27559940
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and completion rates of rifapentine and isoniazid (3HP) compared to other treatment regimens for latent tuberculosis infection: a systematic review with network meta-analyses.
    Pease C; Hutton B; Yazdi F; Wolfe D; Hamel C; Quach P; Skidmore B; Moher D; Alvarez GG
    BMC Infect Dis; 2017 Apr; 17(1):265. PubMed ID: 28399802
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Three months of weekly rifapentine plus isoniazid for latent tuberculosis treatment in solid organ transplant candidates.
    Knoll BM; Nog R; Wu Y; Dhand A
    Infection; 2017 Jun; 45(3):335-339. PubMed ID: 28276008
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment completion for latent tuberculosis infection: a retrospective cohort study comparing 9 months of isoniazid, 4 months of rifampin and 3 months of isoniazid and rifapentine.
    McClintock AH; Eastment M; McKinney CM; Pitney CL; Narita M; Park DR; Dhanireddy S; Molnar A
    BMC Infect Dis; 2017 Feb; 17(1):146. PubMed ID: 28196479
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A systematic review of adverse events of rifapentine and isoniazid compared to other treatments for latent tuberculosis infection.
    Pease C; Hutton B; Yazdi F; Wolfe D; Hamel C; Barbeau P; Skidmore B; Alvarez GG
    Pharmacoepidemiol Drug Saf; 2018 Jun; 27(6):557-566. PubMed ID: 29573031
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An open label, randomised controlled trial of rifapentine versus rifampicin based short course regimens for the treatment of latent tuberculosis in England: the HALT LTBI pilot study.
    Surey J; Stagg HR; Yates TA; Lipman M; White PJ; Charlett A; Muñoz L; Gosce L; Rangaka MX; Francis M; Hack V; Kunst H; Abubakar I
    BMC Infect Dis; 2021 Jan; 21(1):90. PubMed ID: 33478428
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of 3 Months of Once-Weekly Rifapentine and Isoniazid for Latent Tuberculosis Infection.
    Walker RE; Bass S; Srinivas P; Miranda C; Johnson L; Pallotta AM
    Ann Pharmacother; 2020 May; 54(5):457-463. PubMed ID: 31729245
    [No Abstract]   [Full Text] [Related]  

  • 14. Using Video Technology to Increase Treatment Completion for Patients With Latent Tuberculosis Infection on 3-Month Isoniazid and Rifapentine: An Implementation Study.
    Lam CK; McGinnis Pilote K; Haque A; Burzynski J; Chuck C; Macaraig M
    J Med Internet Res; 2018 Nov; 20(11):e287. PubMed ID: 30459146
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Short-course isoniazid plus rifapentine directly observed therapy for latent tuberculosis in solid-organ transplant candidates.
    de Castilla DL; Rakita RM; Spitters CE; Narita M; Jain R; Limaye AP
    Transplantation; 2014 Jan; 97(2):206-11. PubMed ID: 24142036
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment completion for latent tuberculosis infection in Norway: a prospective cohort study.
    Schein YL; Madebo T; Andersen HE; Arnesen TM; Dyrhol-Riise AM; Tveiten H; White RA; Winje BA
    BMC Infect Dis; 2018 Nov; 18(1):587. PubMed ID: 30453946
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recommendations for use of an isoniazid-rifapentine regimen with direct observation to treat latent Mycobacterium tuberculosis infection.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2011 Dec; 60(48):1650-3. PubMed ID: 22157884
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High Rate of Treatment Completion in Program Settings With 12-Dose Weekly Isoniazid and Rifapentine for Latent Mycobacterium tuberculosis Infection.
    Sandul AL; Nwana N; Holcombe JM; Lobato MN; Marks S; Webb R; Wang SH; Stewart B; Griffin P; Hunt G; Shah N; Marco A; Patil N; Mukasa L; Moro RN; Jereb J; Mase S; Chorba T; Bamrah-Morris S; Ho CS
    Clin Infect Dis; 2017 Oct; 65(7):1085-1093. PubMed ID: 28575208
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Isoniazid vs. rifampin for latent tuberculosis infection in jail inmates: toxicity and adherence.
    White MC; Tulsky JP; Lee JR; Chen L; Goldenson J; Spetz J; Kawamura LM
    J Correct Health Care; 2012 Apr; 18(2):131-42. PubMed ID: 22419641
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Self-administered Versus Directly Observed Once-Weekly Isoniazid and Rifapentine Treatment of Latent Tuberculosis Infection: A Randomized Trial.
    Belknap R; Holland D; Feng PJ; Millet JP; Caylà JA; Martinson NA; Wright A; Chen MP; Moro RN; Scott NA; Arevalo B; Miró JM; Villarino ME; Weiner M; Borisov AS;
    Ann Intern Med; 2017 Nov; 167(10):689-697. PubMed ID: 29114781
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.